Key Drivers
- Gross margin strength
- Heavy leverage
- Weak quarter
AIAI Summary
BHC should be viewed less as a broken earnings story and more as a cash-generating, highly levered balance-sheet repair trade: the investment case now hinges on whether steady free cash flow and underlying operating growth can de-risk $20.8B of debt fast enough before reimbursement, IRA, and product headwinds pressure the franchise.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin strength
- •Heavy leverage
- •Weak quarter
BHC generates solid gross profit and cash flow, but its highly leveraged balance sheet, negative equity, and weak latest-quarter results make it a distressed turnaround rather than a low-risk investment.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Rebound failure
- •Downtrend intact
BHC remains short-term bearish, with a defendable $4.67-$4.77 support zone but repeated failures near $5.15-$5.37 and a quick fade after the June 25 rebound.
Sharp rebound to $5.28 on
Sentiment & News
Key News Insights:
- •China certification
- •Aesthetics strength
- •Share weakness
Bausch Health's Solta unit won China trademark certification for Thermage, but BHC shares remain under pressure, down 5.4% since earnings.
The certification is a modest positive for Solta's brand momentum, but near-term investor sentiment on BHC remains cautious after earnings
Similar Companies in Healthcare
Other companies in the same sector with AI ratings